Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share
IBER.WS
IBER.WS was delisted on the 15th of February, 2023.
33 hedge funds and large institutions have $2.43M invested in Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share in 2022 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 5 reducing their positions, and 1 closing their positions.
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
10% more funds holding
Funds holding: 30 → 33 (+3)
35% less capital invested
Capital invested by funds: $3.74M → $2.43M (-$1.31M)
60% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Aristeia Capital
Greenwich,
Connecticut
|
+$52.6K |
| 2 |
CCM
Context Capital Management
Lajolla,
California
|
+$17.3K |
| 3 |
CAC
Cowen and Company
New York
|
+$11.4K |
| 4 |
LCM
Lynwood Capital Management
Toronto,
Ontario, Canada
|
+$4.01K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$511 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCL
Glazer Capital LLC
New York
|
-$53K |
| 2 |
LA
Linden Advisors
New York
|
-$9.69K |
| 3 |
ICMH
Integrity Capital Management (HK)
Central,
Hong Kong
|
-$7.23K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$3.13K |
| 5 |
PCM
Prelude Capital Management
New York
|
-$1.5K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
WA
26
Whitebox Advisors
Minneapolis,
Minnesota
| $7K | -$901 | -3,000 | -8% |
|
|
AC
27
Ayrton Capital
Westport,
Connecticut
| $6K | – | – | – |
|
|
PI
28
PEAK6 Investments
Chicago,
Illinois
| $5K | – | – | – |
|
|
TCM
29
Tegean Capital Management
New York
| $5K | – | – | – |
|
|
PCM
30
Prelude Capital Management
New York
| $3K | -$1.5K | -5,000 | -27% |
|
31
Capstone Investment Advisors
New York
| $3K | – | – | – |
|
|
LCM
32
Lynwood Capital Management
Toronto,
Ontario, Canada
| $3K | +$4.01K | +13,340 | New |
|
|
GCL
33
Glazer Capital LLC
New York
| – | -$53K | -98,705 | Closed |
|
|
34
UBS Group
Zurich,
Switzerland
| – | +$511 | +1,700 | New |
|
IBER.WS Hedge Fund Activity: Q1 2022 in Review
33 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share (IBER.WS) for Q1 2022, worth a combined $2.43M — down 35% from $3.74M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new IBER.WS positions and 1 closed out — a net gain of 3 holders — while 2 added to existing stakes and 5 trimmed.
The largest buyer was Aristeia Capital, opening a new position worth an estimated $52.6K. The largest seller was Glazer Capital LLC, exiting entirely with an estimated $53K sold.
- 33 institutional investors held Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share (IBER.WS) as of Q1 2022, up from 30 in Q4 2021.
- Funds reported $2.43M of Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share stock for Q1 2022, down 35% quarter-over-quarter.
- 4 funds opened new Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share positions in Q1 2022 and 1 closed out, a net change of +3 holders.
- The largest Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share buyer in Q1 2022 was Aristeia Capital, an estimated $52.6K added.
- The largest Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share seller in Q1 2022 was Glazer Capital LLC, an estimated $53K sold.
Based on aggregated 13F filings for Q1 2022.